KINERETRXHCP.COM: Keyword Density Checker

Total words: 2543 | 2-word phrases: 669 | 3-word phrases: 733 | 4-word phrases: 761

PAGE INFO

Title	Try to keep the title under 60 characters (48 characters) KINERET® (anakinra) Official HCP Website \| Home
Description	Try to keep the meta description between 50 - 160 characters (0 characters)
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (110 characters) KINERET® (anakinra) blocks the interleukin-1 (IL-1) receptor to help protect against autoinflammatory events1

#	Keyword	Frequency	Density
1	ra the most	4	0.55%
2	important safety information	4	0.55%
3	infections use in	3	0.41%
4	dira patients the	3	0.41%
5	of a disease	3	0.41%
6	a disease flare	3	0.41%
7	disease flare when	3	0.41%
8	weighed against the	3	0.41%
9	potential risk of	3	0.41%
10	risk of continued	3	0.41%
11	of continued treatment	3	0.41%
12	continued treatment do	3	0.41%
13	in patients with	3	0.41%
14	initiate kineret in	3	0.41%
15	or dira patients	3	0.41%
16	patients with active	3	0.41%
17	with active infections	3	0.41%
18	active infections use	3	0.41%
19	agents is not	3	0.41%
20	about how il1	3	0.41%
21	learn about how	3	0.41%
22	tnfblocking agents is	3	0.41%
23	factor tnfblocking agents	3	0.41%
24	risk of a	3	0.41%
25	discontinuing kineret treatment	3	0.41%
26	with tumor necrosis	3	0.41%
27	ra discontinue use	3	0.41%
28	nomid or dira	3	0.41%
29	kinerettreated nomid or	3	0.41%
30	in ra discontinue	3	0.41%

#	Keyword	Frequency	Density
1	tnfblocking agents is not	3	0.39%
2	of a disease flare	3	0.39%
3	kinerettreated nomid or dira	3	0.39%
4	learn about how il1	3	0.39%
5	infections in ra discontinue	3	0.39%
6	in ra discontinue use	3	0.39%
7	potential risk of continued	3	0.39%
8	risk of continued treatment	3	0.39%
9	of continued treatment do	3	0.39%
10	factor tnfblocking agents is	3	0.39%
11	a disease flare when	3	0.39%
12	patients with active infections	3	0.39%
13	nomid or dira patients	3	0.39%
14	active infections use in	3	0.39%
15	with active infections use	3	0.39%
16	moderately to severely active	2	0.26%
17	discontinuing kineret treatment should	2	0.26%
18	when discontinuing kineret treatment	2	0.26%
19	flare when discontinuing kineret	2	0.26%
20	or dira patients the	2	0.26%
21	dira patients the risk	2	0.26%
22	of structural damage in	2	0.26%
23	the risk of a	2	0.26%
24	progression of structural damage	2	0.26%
25	and symptoms and slowing	2	0.26%
26	disease flare when discontinuing	2	0.26%
27	arthritis ra reduction in	2	0.26%
28	risk of a disease	2	0.26%
29	the progression of structural	2	0.26%
30	ra reduction in signs	2	0.26%
31	weighed against the potential	2	0.26%
32	rheumatoid arthritis ra reduction	2	0.26%
33	with tumor necrosis factor	2	0.26%
34	to help protect against	2	0.26%
35	receptor to help protect	2	0.26%
36	il1 receptor to help	2	0.26%
37	interleukin1 il1 receptor to	2	0.26%
38	in patients with active	2	0.26%
39	infections use in combination	2	0.26%
40	not initiate kineret in	2	0.26%

#	URL	Whois	Check
1	https://www.kineretrx.com/	Whois	kineretrx.com
2	https://www.sobi.com/usa/en/privacy-policy-us	Whois	sobi.com
3	https://sobi-northamerica.com/terms-use	Whois	sobi-northamerica.com
4	https://sobi-northamerica.com/contact-us	Whois	sobi-northamerica.com